Trial · NCT07909538
The Effectiveness of Structured Swallowing Exercise Therapy in Patients With Nasopharyngeal Carcinoma: An Assessment of Swallowing Function and Quality of Life
NCT07909538, Not applicable, Recruiting, Ira Mistivani, dr. Sp.KFR.N.M.(K).
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Effectiveness of Structured Swallowing Exercise Therapy in Patients With Nasopharyngeal Carcinoma: An Assessment of Swallowing Function and Quality of Life. Trials, record NCT07909538. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07909538
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Effectiveness of Structured Swallowing Exercise Therapy in Patients With Nasopharyngeal Carcinoma: An Assessment of Swallowing Function and Quality of Life
- NCT number
- NCT07909538
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 88 participants, estimated
- Lead sponsor
- Ira Mistivani, dr. Sp.KFR.N.M.(K).
- Conditions
- Nasopharyngeal Carcinoma (NPC)
- Interventions
- Structured Swallowing Exercise, Conventional Swallowing Exercise
- First posted
- 2026-11-02
- Last updated
- 2026-11-02
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Hyolaryngeal Excursion from Baseline to Week 8 | Baseline and Week 8 | Hyolaryngeal excursion (HLE) assessed during VFSS by frame-by-frame analysis of hyoid bone displacement during swallowing. HLE is calculated from the anterior and superior displacement of the hyoid bone between its resting position and maximal elevation during swallowing and expressed in millimeters (mm). The outcome will be assessed as the change in HLE from baseline to week 8, with greater excursion indicating greater hyolaryngeal movement. |
| Primary | Change in Penetration-Aspiration Scale (PAS) Score from Baseline to Week 8 | Baseline and Week 8 | Penetration-Aspiration Scale (PAS) score assessed during videofluoroscopic swallowing study (VFSS) to evaluate airway penetration and aspiration during swallowing. The PAS is an 8-point scale, ranging from 1 to 8, with higher scores indicating more severe airway invasion. The outcome will be assessed as the change in PAS score from baseline to week 8. |
| Primary | Change in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Head and Neck 35 (EORTC QLQ-H&N35) Score from Baseline to Week 8 | Baseline and Week 8 | Health-related quality of life assessed using the validated Indonesian version of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Head and Neck 35 (EORTC QLQ-H\&N35). The questionnaire assesses symptoms and problems related to head and neck cancer, including swallowing, eating, social contact, dry mouth, thick saliva, pain, speech, and other disease- or treatment-related symptoms. Scores are transformed to a 0-100 scale, with higher scores indicating greater symptom burden or problems and therefore worse symptom-related quality of life. The outcome will be assessed as the change in score from baseline to week 8. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers11
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07909538
GET https://conductscience.org/api/trials/v1/NCT07909538/registered